Nimesulide

MUSCULO-SKELETAL SYSTEM

Key facts

Nimesulide is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1985. DrugCentral lists 11 molecular targets, including PTGS2, PTGS2 and PDE4A.

• Molecular targets: PTGS2, PTGS2, PDE4A and MPO (11 listed in DrugCentral).
• ATC code: M01AX17 (Other antiinflammatory and antirheumatic agents, non-steroids).
• Molecular formula: C13H12N2O5S; molecular weight 308.31 g/mol.

Mechanism & targets

Molecular targets (11)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 6.40
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 5.91
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	PDE4A	unknown	IC50 5.70
Myeloperoxidase	MPO	unknown	IC50 5.68
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 5.42
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 5.21
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 4.93
Sodium-dependent neutral amino acid transporter B(0)AT1	Slc6a19	inhibitor	IC50 4.64
Interstitial collagenase	MMP1	unknown	IC50 4.63
Aromatase	CYP19A1	unknown	IC50 4.57
Dipeptidyl peptidase 3	—	unknown	Ki 4.16

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
M01AX17	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Other antiinflammatory and antirheumatic agents, non-steroids
M02AA26	MUSCULO-SKELETAL SYSTEM › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › Antiinflammatory preparations, non-steroids for topical use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Amaurosis fugax	773.0
Ocular discomfort	672.9
Haemorrhagic stroke	651.4
Urinary tract disorder	620.9
Head discomfort	609.5
Generalised oedema	513.1
Haematemesis	502.9
Blindness	502.6
Altered state of consciousness	501.1
Eye pain	467.4
Diplopia	414.0
Presyncope	408.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nimesulide is on its molecule page.

• Molecular formula: C₁₃H₁₂N₂O₅S
• Molecular weight: 308.31 g/mol
• CAS number: 51803-78-2
• InChIKey: HYWYRSMBCFDLJT-UHFFFAOYSA-N
• PubChem CID: 4495

CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Nimesulide work?

Its molecular targets in DrugCentral include PTGS2, PTGS2, PDE4A and MPO.

When was Nimesulide first approved?

Nimesulide was first approved by the YEAR INTRODUCED in 1985.

What is the chemical formula of Nimesulide?

Nimesulide has the molecular formula C13H12N2O5S and a molecular weight of 308.31 g/mol.

Sources

• DrugCentral drug card 1935 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL56367 — compound record and bioactivity
• PubChem CID 4495 — chemical identifiers
• DrugBank DB04743 — drug record
• FDA UNII V4TKW1454M — substance identity
• UniProt P35354 (PTGS2) — target protein
• UniProt P27815 (PDE4A) — target protein
• UniProt P05164 (MPO) — target protein
• UniProt P23219 (PTGS1) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P03956 (MMP1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.